PT - JOURNAL ARTICLE AU - Sarah E Hughes AU - Shamil Haroon AU - Anuradhaa Subramanian AU - Christel McMullan AU - Olalekan L Aiyegbusi AU - Grace M Turner AU - Louise Jackson AU - Elin Haf Davies AU - Chris Frost AU - Gary McNamara AU - Gary Price AU - Karen Matthews AU - Jennifer Camaradou AU - Jane Ormerod AU - Anita Walker AU - Melanie J Calvert TI - Development and validation of the Symptom Burden Questionnaire™ for Long Covid: A Rasch analysis AID - 10.1101/2022.01.16.22269146 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.16.22269146 4099 - http://medrxiv.org/content/early/2022/01/17/2022.01.16.22269146.short 4100 - http://medrxiv.org/content/early/2022/01/17/2022.01.16.22269146.full AB - Objective To describe the development and initial validation of a novel patient-reported outcome measure of Long COVID symptom burden, the Symptom-Burden Questionnaire for Long COVID (SBQ™-LC).Method and Findings This multi-phase, prospective mixed-methods study took place between April and August 2021 in the United Kingdom (UK). A conceptual framework and initial item pool were developed from published systematic reviews. Further concept elicitation and content validation was undertaken with adults with lived experience (n = 13) and clinicians (n = 10), and face validity was confirmed by the Therapies for Long COVID Study Patient and Public Involvement group (n = 25). The draft SBQ™-LC was field tested by adults with self-reported Long COVID recruited via social media and international Long COVID support groups (n = 274). Thematic analysis of interview and survey transcripts established content validity and informed construction of the draft questionnaire. Rasch analysis of field test data guided item and scale refinement and provided evidence of the final SBQ™-LC’s measurement properties. The Rasch-derived SBQ™-LC is composed of 17 independent scales with promising psychometric properties. Respondents rate symptom burden during the past 7-days using a dichotomous response or 4-point rating scale. Each scale provides coverage of a different symptom domain and returns a summed raw score that may be converted to a linear (0 – 100) score. Higher scores represent higher symptom burden.Conclusions The SBQ™-LC is a comprehensive patient-reported assessment of Long COVID symptom burden developed using modern psychometric methods. It measures symptoms of Long COVID important to individuals with lived experience and may be used to evaluate the impact of interventions and inform best practice in clinical management.Competing Interest StatementSEH receives funding from the National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) West Midlands, UK Research and Innovation (UKRI) and declares personal fees from Aparito Limited and Cochlear Limited outside the submitted work. MJC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. MJC receives funding from the National Institute for Health Research (NIHR), UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR ARC West Midlands, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. MC has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. OLA receives funding from the NIHR Birmingham BRC, West Midlands, Birmingham, NIHR ARC West Midlands, UKRI, Health Foundation, Janssen, Gilead and GSK. He declares personal fees from Gilead Sciences Ltd, Merck and GSK outside the submitted work. JC is a lay member on the UK NICE COVID expert panel, a citizen partner to the COVID END Evidence Synthesis Network, PPI lead on the NIHR CICADA ME Study, patient representative at the EAN European Neurology Autonomic Nervous Systems Disorders Working Group, a member of the MRC/UKRI Advanced Pain Discovery Platform, and external board member of Plymouth Institute of Health. She also reports contracts with GSK and Medable. CM receives funding from NIHR SRMRC, UKRI, and declares personal fees from Aparito Ltd. KM is employed by the NIHR. SH receives funding from NIHR and UKRI. No other disclosures were reported.Funding StatementThis work is independent research jointly funded by the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI) (Therapies for Long COVID in non-hospitalized individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (The TLC Study), COV-LT-0013). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, or UKRI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee of the University of Birmingham gave ethical approval for this work (Reference: ERN_21-0191).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this project are not currently available for access outside the TLC research team. The dataset may be shared when finalised but this will require an application to the data controllers. The data may then be released to a specific research team for a specific project dependent on the independent approvals being in place.